Insuman Comb 15

Insulin human, the active ingredient in Insuman Comb 15, is an insulin presented as a sterile solution for subcutaneous use. It lowers blood glucose by facilitating cellular uptake and suppressing hepatic glucose production, and is prescribed for patients with type 1 or type 2 diabetes mellitus.

GNH USA supplies Insuman Comb 15 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for importation. Customers benefit from reliable cold‑chain logistics and responsive technical assistance.

Insuman Comb 15 is an insulin used to manage hyperglycemia in diabetes mellitus.

Diabetes mellitus type 1: replaces deficient endogenous insulin to achieve glycaemic control. Diabetes mellitus type 2: provides supplemental insulin when oral agents are insufficient. Pre‑operative glucose control in diabetic patients: stabilises blood sugar before surgery.

Insuman Comb 15 may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: symptoms of low blood sugar such as shakiness, sweating, or confusion. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight due to improved glucose utilisation. - Edema: mild fluid retention, especially in the lower extremities. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe hypoglycaemia with loss of consciousness or seizures. - Anaphylactic reaction: difficulty breathing, hives, or swelling of the face. - Serum sickness‑like reaction: fever, rash, arthralgia. - Severe local infection at the injection site.

When using Insuman Comb 15, consider the following precautions.

Dose adjustment: tailor the insulin dose based on regular blood‑glucose monitoring. Renal impairment: monitor closely as insulin clearance may be reduced. Hepatic impairment: use with caution; altered glucose metabolism may occur. Pregnancy: limited safety data; evaluate risk‑benefit before prescribing. Hypoglycaemia risk: educate patients on recognising and treating low blood sugar. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 15 can interact with several medicines.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms. - MAO inhibitors: can potentiate insulin‑induced hypoglycaemia. - Alcohol: enhances insulin effect and increases hypoglycaemia risk.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose, requiring dose adjustment. - Corticosteroids: can increase glucose levels, possibly necessitating higher insulin doses. - ACE inhibitors: may affect potassium balance and require monitoring.